公开(公告)号：US09696307B2

公开(公告)日：2017-07-04

申请号：US14603002

申请日：2015-01-22

Applicant: Biogen Idec MA Inc.

Inventor： Leonid Gorelik ,  Alexey Lugovskoy

IPC: G01N33/569 ,  C07K16/08 ,  G01N33/53

CPC classification number: G01N33/56983 ,  C07K16/081 ,  C07K2317/33 ,  G01N2333/025 ,  G01N2469/20 ,  G01N2800/28 ,  G01N2800/50 ,  G01N2800/52

Abstract: Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.

公开(公告)号：US09228015B2

公开(公告)日：2016-01-05

申请号：US14146345

申请日：2014-01-02

Applicant: Biogen Idec MA Inc.

Inventor： Daniel H. S. Lee ,  Dingyi Wen ,  R. Blake Pepinsky ,  Jane K. Relton ,  Xinzhong Wang ,  Alexey Lugovskoy ,  Werner Meier ,  Ellen A. Garber ,  Laura Silvian ,  Paul H. Weinreb

IPC: C07K16/28 ,  A01K67/027 ,  C07K14/705 ,  C12N15/113 ,  C12N15/85 ,  A61K38/17 ,  A61K39/395 ,  A61K48/00 ,  A61K39/00

CPC classification number: C07K14/705 ,  A01K67/027 ,  A01K67/0275 ,  A01K2217/058 ,  A01K2227/105 ,  A01K2267/0356 ,  A61K38/179 ,  A61K39/3955 ,  A61K48/00 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/33 ,  C07K2319/74 ,  C12N15/1136 ,  C12N15/1138 ,  C12N15/8509 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53

Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Abstract translation: 公开了免疫原性Nogo受体-1多肽，Nogo受体-1抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白和编码其的核酸。 还公开了Nogo受体拮抗剂多核苷酸。 还公开了包含这样的Nogo受体抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白，编码相同的核苷酸和拮抗剂多核苷酸的制备和使用方法。

公开(公告)号：US20150219651A1

公开(公告)日：2015-08-06

申请号：US14603002

申请日：2015-01-22

Applicant: Biogen Idec MA Inc.

Inventor： Leonid Gorelik ,  Alexey Lugovskoy

IPC: G01N33/569

CPC classification number: G01N33/56983 ,  C07K16/081 ,  C07K2317/33 ,  G01N2333/025 ,  G01N2469/20 ,  G01N2800/28 ,  G01N2800/50 ,  G01N2800/52

Abstract: Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.

Abstract translation: 呈现用于确定受试者是否处于PML风险中的方法和组合物，包括用免疫抑制剂治疗的受试者，通过确定受试者是否携带具有减少的唾液酸相对于正常JCV的结合的JCV变体。 此外，与PML相关的JCV-VP1序列变异的组合可用作用于鉴定易受PML影响的受试者（例如早期PML）或具有发展PML风险的受试者的测定的基础 响应于免疫抑制治疗。

公开(公告)号：US08961976B2

公开(公告)日：2015-02-24

申请号：US14134753

申请日：2013-12-19

Applicant: Biogen Idec Ma Inc.

Inventor： Herman Van Vlijmen ,  Alexey Lugovskoy ,  Karl Hanf

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2875 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  Y10S435/81

Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.

Abstract translation: 本发明提供了肽及其片段，以及包含其的抗体或其片段，其中与野生型5c8抗体相比，该肽包含至少一个氨基酸取代。 本发明还提供了治疗受试者中CD154相关疾病或病症的组合物和方法。

公开(公告)号：US20140227266A1

公开(公告)日：2014-08-14

申请号：US14146345

申请日：2014-01-02

Applicant: Biogen Idec MA Inc.

Inventor： Daniel H.S. Lee ,  Dingyi Wen ,  R. Blake Pepinsky ,  Jane K. Relton ,  Xinzhong Wang ,  Alexey Lugovskoy ,  Werner Meier ,  Ellen A. Garber ,  Laura Silvian ,  Paul H. Weinreb

IPC: C07K16/28 ,  A61K38/17 ,  C12N15/113 ,  C07K14/705 ,  A61K39/395

CPC classification number: C07K14/705 ,  A01K67/027 ,  A01K67/0275 ,  A01K2217/058 ,  A01K2227/105 ,  A01K2267/0356 ,  A61K38/179 ,  A61K39/3955 ,  A61K48/00 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/33 ,  C07K2319/74 ,  C12N15/1136 ,  C12N15/1138 ,  C12N15/8509 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53

Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Abstract translation: 公开了免疫原性Nogo受体-1多肽，Nogo受体-1抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白和编码其的核酸。 还公开了Nogo受体拮抗剂多核苷酸。 还公开了包含这样的Nogo受体抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白，编码相同的拮抗剂多核苷酸的核酸和制备和使用的组合物。

公开(公告)号：US20130101549A1

公开(公告)日：2013-04-25

申请号：US13660238

申请日：2012-10-25

Applicant: BIOGEN IDEC MA INC.

Inventor： Xinzhong Wang ,  Veronique Bailly ,  Graham K. Farrington ,  Alexey Lugovskoy

IPC: C07K16/30 ,  C07K14/525

CPC classification number: C07K16/30 ,  C07K14/525 ,  C07K14/7151 ,  C07K2319/01 ,  G01N33/57415

Abstract: LIGHT-targeting molecules (e.g., LIGHT fusion molecules), compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.

Abstract translation: 公开了光靶向分子（例如，LIGHT融合分子），组合物，例如其药物组合物。 还提供了使用这些分子来治疗，预防和/或诊断过度增殖，例如肿瘤性疾病或病症（包括但不限于癌症和转移）的方法。